Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Veronica Lisi is active.

Publication


Featured researches published by Veronica Lisi.


Stem Cells | 2008

Toll-Like Receptors 3 and 4 Are Expressed by Human Bone Marrow-Derived Mesenchymal Stem Cells and Can Inhibit Their T-Cell Modulatory Activity by Impairing Notch Signaling

Francesco Liotta; Roberta Angeli; Lorenzo Cosmi; Lucia Filì; Cinzia Manuelli; Francesca Frosali; Benedetta Mazzinghi; Laura Maggi; Annalisa Pasini; Veronica Lisi; Veronica Santarlasci; Lara Consoloni; Maria Lucia Angelotti; Paola Romagnani; Paola Parronchi; Mauro Krampera; Enrico Maggi; Sergio Romagnani; Francesco Annunziato

Bone marrow (BM)‐derived mesenchymal stem cells (MSCs) are multipotent, nonhemopoietic progenitors that also possess regulatory activity on immune effector cells through different mechanisms. We demonstrate that human BM‐derived MSCs expressed high levels of Toll‐like receptors (TLRs) 3 and 4, which are both functional, as shown by the ability of their ligands to induce nuclear factor κB (NF‐κB) activity, as well as the production of interleukin (IL)‐6, IL‐8, and CXCL10. Of note, ligation of TLR3 and TLR4 on MSCs also inhibited the ability of these cells to suppress the proliferation of T cells, without influencing their immunophenotype or differentiation potential. The TLR triggering effects appeared to be related to the impairment of MSC signaling to Notch receptors in T cells. Indeed, MSCs expressed the Notch ligand Jagged‐1, and TLR3 or TLR4 ligation resulted in its strong downregulation. Moreover, anti‐Jagged‐1 neutralizing antibody and N[N‐(3,5‐difluorophenacetyl‐l‐alanyl)]‐S‐phenylglycine t‐butyl ester (DAPT), an inhibitor of Notch signaling, hampered the suppressive activity of MSCs on T‐cell proliferation. These data suggest that TLR3 and TLR4 expression on MSCs may provide an effective mechanism to block the immunosuppressive activity of MSCs and therefore to restore an efficient T‐cell response in the course of dangerous infections, such as those sustained by double‐stranded RNA viruses or Gram‐negative bacteria, respectively.


Stem Cells | 2011

Toll‐Like Receptor‐3‐Activated Human Mesenchymal Stromal Cells Significantly Prolong the Survival and Function of Neutrophils

Marco A. Cassatella; Federico Mosna; Alessandra Micheletti; Veronica Lisi; Nicola Tamassia; Caterina Cont; Federica Calzetti; Martin Pelletier; Giovanni Pizzolo; Mauro Krampera

Bone marrow‐derived mesenchymal stromal cells (BM‐MSCs) are stromal precursors endowed with extensive immunomodulative properties. In this study, we aimed to assess whether Toll‐like receptor‐3 (TLR3)‐ and TLR4‐activated BM‐MSC influence human neutrophil (PMN) responses under coculture conditions. We show that TLR3 triggering by polyinosinic:polycytidylic acid dramatically amplifies, in a more significant manner than TLR4 triggering by lipopolysaccharide, the antiapoptotic effects that resting BM‐MSC constitutively exert on PMN under coculture conditions, preserving a significant fraction of viable and functional PMN up to 72 hours. In addition, TLR3‐ and TLR4‐activated BM‐MSC enhance respiratory burst ability and CD11b expression by PMN. The coculture in the absence of cell contact and the incubation of PMN in supernatants harvested from TLR3‐ and TLR4‐activated BM‐MSC yield comparable results in terms of increased survival and immunophenotypic changes, thus suggesting the involvement of endogenous soluble factors. Neutralizing experiments reveal that the biological effects exerted on PMN by TLR3‐activated BM‐MSC are mediated by the combined action of interleukin 6, interferon‐β (IFN‐β), and granulocyte macrophage colony‐stimulating factor (GM‐CSF), while those exerted by TLR4‐activated BM‐MSC mostly depend on GM‐CSF. MSC isolated from thymus, spleen, and subcutaneous adipose tissue behaves similarly. Finally, the effects exerted by TLR3‐ or TLR4‐stimulated BM‐MSC on PMN are conserved even after the previous priming of BM‐MSC with IFN‐γ and tumor necrosis factor‐α. Our data highlight a novel mechanism by which MSC sustain and amplify the functions of PMN in response to TLR3‐ and TLR4‐triggering and may consequently contribute to inflammatory disorders. STEM CELLS 2011;29:1001–1011


Blood | 2011

Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow―derived mesenchymal stromal cells

Armel Herve Nwabo Kamdje; Federico Mosna; Francesco Bifari; Veronica Lisi; Giulio Bassi; Giorgio Malpeli; Mario Ricciardi; Omar Perbellini; Maria Teresa Scupoli; Giovanni Pizzolo; Mauro Krampera

Although many literature data are available on the role of Notch signaling in T-cell acute lymphoblastic leukemia (ALL) biology, the importance of this molecular pathway in the development of B-lineage ALL (B-ALL) cells in the BM microenvironment is unknown so far. In this study, we used anti-Notch molecules neutralizing Abs and γ-secretase inhibitor (GSI) XII to investigate the role of the Notch signaling pathway in the promotion of human B-ALL cell survival in presence of stromal cell support. The treatment with combinations of anti-Notch molecule neutralizing Abs resulted in the decrease of B-ALL cell survival, either cultured alone or cocultured in presence of stromal cells from normal donors and B-ALL patients. Interestingly, the inhibition of Notch-3 and -4 or Jagged-1/-2 and DLL-1 resulted in a dramatic increase of apoptotic B-ALL cells by 3 days, similar to what is obtained by blocking all Notch signaling with the GSI XII. Our data suggest that the stromal cell-mediated antiapoptotic effect on B- ALL cells is mediated by Notch-3 and -4 or Jagged-1/-2 and DLL-1 in a synergistic manner.


Journal of Cellular and Molecular Medicine | 2009

Novel stem/progenitor cells with neuronal differentiation potential reside in the leptomeningeal niche

Francesco Bifari; Ilaria Decimo; Cristiano Chiamulera; Emanuela Bersan; Giorgio Malpeli; Jan Johansson; Veronica Lisi; Bruno Bonetti; Guido Fumagalli; Giovanni Pizzolo; Mauro Krampera

Stem cells capable of generating neural differentiated cells are recognized by the expression of nestin and reside in specific regions of the brain, namely, hippocampus, subventricular zone and olfactory bulb. For other brain structures, such as leptomeninges, which contribute to the correct cortex development and functions, there is no evidence so far that they may contain stem/precursor cells. In this work, we show for the first time that nestin‐positive cells are present in rat leptomeninges during development up to adulthood. The newly identified nestin‐positive cells can be extracted and expanded in vitro both as neurospheres, displaying high similarity with subventricular zone–derived neural stem cells, and as homogeneous cell population with stem cell features. In vitro expanded stem cell population can differentiate with high efficiency into excitable cells with neuronal phenotype and morphology. Once injected into the adult brain, these cells survive and differentiate into neurons, thus showing that their neuronal differentiation potential is operational also in vivo. In conclusion, our data provide evidence that a specific population of immature cells endowed of neuronal differentiation potential is resident in the leptomeninges throughout the life. As leptomeninges cover the entire central nervous system, these findings could have relevant implications for studies on cortical development and for regenerative medicine applied to neurological disorders.


Transfusion Medicine and Hemotherapy | 2008

Immune Modulation by Mesenchymal Stem Cells

Francesco Bifari; Veronica Lisi; Elda Mimiola; Annalisa Pasini; Mauro Krampera

Mesenchymal stem cells (MSCs) and their stromal progeny may be considered powerful regulatory cells, a sort of dendritic cell counterpart, which influence all the main immune effectors and functional roles in vivo, as well as potential applications in the treatment of a number of human immunological diseases. By choosing MSC tissue origin, cell dose, administration route, and treatment schedule, all the potential side effects related to MSC use, including tumor growth enhancement, have to be well considered to maximize the benefits of MSC-dependent immune regulation without significant risks for the patients.


Stem Cells and Development | 2011

Efficacy Assessment of Interferon-Alpha–Engineered Mesenchymal Stromal Cells in a Mouse Plasmacytoma Model

Silvia Sartoris; Marta Mazzocco; Martina Tinelli; Matteo Martini; Federico Mosna; Veronica Lisi; Stefano Indraccolo; Lidia Moserle; Tiziana Cestari; Anna Pia Riviera; Francesco Bifari; Giuseppe Tridente; Giovanni Pizzolo; Mauro Krampera

Bone marrow mesenchymal stromal cells (BM-MSCs) may survive and proliferate in the presence of cycling neoplastic cells. Exogenously administered MSCs are actively incorporated in the tumor as stromal fibroblasts, thus competing with the local mesenchymal cell precursors. For this reason, MSCs have been suggested as a suitable carrier for gene therapy strategies, as they can be genetically engineered with genes encoding for biologically active molecules that can inhibit tumor cell proliferation and enhance the antitumor immune response. We used BM-MSCs engineered with the murine interferon-alpha (IFN-α) gene (BM-MSCs/IFN-α) to assess in a mouse plasmacytoma model the efficacy of this approach toward neoplastic plasma cells. We found that IFN-α can be efficiently produced and delivered inside the tumor microenvironment. Subcutaneous multiple administration of BM-MSCs/IFN-α significantly hampered the tumor growth in vivo and prolonged the overall survival of mice. The antitumor effect was associated with enhanced apoptosis of tumor cells, reduction in microvessel density, and ischemic necrosis. By contrast, intravenous administration of BM-MSCs/IFN-α did not significantly modify the survival of mice, mainly as a consequence of an excessive entrapment of injected cells in the pulmonary vessels. In conclusion, BM-MSCs/IFN-α are effective in inhibiting neoplastic plasma cell growth; however, systemic administration of engineered MSCs needs to be improved to make this approach potentially suitable for the treatment of multiple myeloma.


Human Mutation | 1998

Four new cases of lethal osteogenesis imperfecta due to glycine substitutions in COL1A1 and genes

Monica Mottes; Macarena Gomez Lira; Francesca Zolezzi; Maurizia Valli; Veronica Lisi; Peter Freising

Van Hippel-Lindau disease (VHL) is an autosomal dominantly inherited disorder, characterised by the development of clear cell renal carcinomas, CNS hemangioblastomas, retinal angiomas, pancreatic tumors, pheochromocytomas and hepatic cysts. Recently a number of families with dominant familial pheochromocytoma as the only clinical manifestation have been reported to carry mutations in the HVL gene. We describe a family in which a novel VHL S68W mutation was segregating and carrier individuals manifested with variable penetrance of isolated pheochromocytomas. Investigation of this kindred confirmed that a mutation in the VHL gene could produce isolated pheochromocytomas as the only clinical feature and was variably penetrant.Perinatal lethal osteogenesis imperfecta is the result of heterozygous mutations of the COL1A1 and COL1A2 genes. Here we describe the molecular defects responsible for four cases of lethal OI. Two glycine substitutions within the COL1A1 gene (G478S, G994D) and two glycine substitutions within the COL1A2 gene (G319V, G697C) were identified. The mutation sites were localized in proalpha2(I)and proalpha2(I)mRNA molecules, respectively, by chemical cleavage of mismatch in heteroduplex nucleic acids. Subsequent reverse transcription‐ PCR amplification, cloning and sequencing, led to mutation identification. The amino acid substitutions were due to two G→A transitions in COL1A1(cases 1,2), to a G→T transversion in COL1A2 (case 3), and to two contiguous point mutations in COL1A2 (case 4). All five nucleotide changes appeared to be fresh mutations.


Human Heredity | 2000

Allelic Frequencies of FBN1 Gene Polymorphisms and Genetic Analysis of Italian Families with Marfan Syndrome

Monica Mottes; Stefania Mirandola; Federica Rigatelli; Francesca Zolezzi; Veronica Lisi; Derek Gordon; Pier Franco Pignatti

The fibrillin gene (FBN1) is the disease locus for Marfan syndrome. This disorder shows a high degree of clinical and allelic heterogeneity. Direct mutation screening has proven difficult and inefficient and at present cannot be utilized for routine analysis. In familial cases linkage analysis represents a useful tool for molecular diagnosis. We have determined the allelic frequencies of 5 polymorphic markers within the FBN1 locus in the Italian population and have successfully employed them for prenatal diagnosis and resolution of clinically equivocal cases.


Experimental Cell Research | 2008

Stem molecular signature of adipose-derived stromal cells.

Daniele Peroni; Ilaria Scambi; Annalisa Pasini; Veronica Lisi; Francesco Bifari; Mauro Krampera; Gino Rigotti; Andrea Sbarbati; Mirco Galiè


Genetic Counseling | 2002

Linkage analysis for prenatal diagnosis in a familial case of Stickler syndrome

Veronica Lisi; A Guala; A Lopez; M Vitali; E Spadoni; C Olivieri; C Danesino; Monica Mottes

Collaboration


Dive into the Veronica Lisi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge